1. Bone Marrow Microenvironment in Multiple Myeloma Progression. (3rd October 2012) Authors: Manier, S.; Sacco, A.; Leleu, X.; Ghobrial, I. M.; Roccaro, A. M. Other Names: Lin Sue-Hwa Academic Editor. Journal: Journal of biomedicine and biotechnology Issue: Volume 2012(2012) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. P1257: MOLECULAR CHARACTERIZATION AND CLONAL EVOLUTION OF MYCOSIS FUNGOIDES. (23rd June 2022) Authors: Fléchon, L.; Arib, I.; Dutta, A.; Sklanvenitis Pistofidis, R.; Stewart, C.; Dubois, R.; Poulain, S.; Copin, M.-C.; Javed, S.; Nudel, M.; Hasan Bou Issa, L.; Ouelkite-Oumouchal, A.; Faiz, S.; Carpentier, O.; Mortier, L.; Mitra, S.; Figeac, M.; Morschhauser, F.; Quesnel, B.; Ghobrial, I. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 1142 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. P851: TARGETING GENE DEPENDENCIES IN MYC OVEREXPRESSING MULTIPLE MYELOMA. (23rd June 2022) Authors: Hasan Bou Issa, L.; Fléchon, L.; Laine, W.; Ouelkdite, A.; Escure, G.; Gaggero, S.; Ingegnere, T.; Sklavenitis Pistofidis, R.; Ghobrial, I. M.; Facon, T.; Mitra, S.; Kluza, J.; Quesnel, B.; Manier, S. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 745 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. P866: CORRELATIVE ANALYSIS TO DEFINE PATIENT PROFILES ASSOCIATED WITH MANUFACTURING AND CLINICAL ENDPOINTS IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS TREATED WITH IDECABTAGENE VICLEUCEL (BB2121). (23rd June 2022) Authors: Rytlewski, J.; Fuller, J.; Mertz, D. R.; Freeman, C.; Manier, S.; Shah, N.; Campbell, T. B. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 759 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. P872: DEL(1P32) REMAINS A POWERFUL PROGNOSTIC FACTOR IN A LARGE COHORT OF NDMM PATIENTS: AN UPDATE. (23rd June 2022) Authors: Schavgoulidze, A.; Perrot, A.; Cazaubiel, T.; Leleu, X.; Manier, S.; Buisson, L.; Maheo, S.; Do Souto Ferreira, L.; Lannes, R.; Pavageau, L.; Hulin, C.; Marolleau, J.-P.; Voillat, L.; Belhadj, K.; Divoux, M.; Slama, B.; Brechignac, S.; Macro, M.; Stoppa, A.-M.; Sanhes, L. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 765 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. P891: IXAZOMIB, POMALIDOMIDE AND DEXAMETHASONE (IXPD) IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM) CHARACTERIZED WITH HIGH-RISK CYTOGENETICS. IFM 2014-01. (23rd June 2022) Authors: Bobin, A.; Manier, S.; De Keizer, J.; Karlin, L.; Perrot, A.; Hulin, C.; Caillot, D.; Mariette, C.; Lenain, P.; Richez, V.; Tiab, M.; Touzeau, C.; Jaccard, A.; Decaux, O.; Araujo, C.; Belhadj, K.; Benboubker, L.; Déal, C.; Macro, M.; Vincent, L. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 783 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. P929: IXAZOMIB AND DARATUMUMAB WITHOUT DEXAMETHASONE (I-DARA) IN ELDERLY FRAIL RELAPSING MYELOMA (RRMM) PATIENTS: RESULTS OF THE PHASE 2 STUDY IFM 2018-02 OF THE INTERGROUPE FRANCOPHONE DU MYELOME (IFM). (23rd June 2022) Authors: Macro, M.; Touzeau, C.; Mariette, C.; Manier, S.; Brechignac, S.; Vincent, L.; Hebraud, B.; Decaux, O.; Schulmann, S.; Lenoir, C.; Godmer, P.; Farge, A.; Peyro Saint Paul, L.; Parienti, J.-J.; Leleu, X. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 819 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. P957: CARFILZOMIB, LENALIDOMIDE, DEXAMETHASONE FOLLOWED BY A SECOND AUTO-HCT IS AN EFFECTIVE STRATEGY IN FIRST RELAPSE MULTIPLE MYELOMA: A STUDY OF THE CHRONIC MALIGNANCIES WORKING PARTY OF EBMT. (23rd June 2022) Authors: Tilmont, R.; Yakoub-Agha, I.; Eikema, D.-J.; Zinger, N.; Haenel, M.; Schaap, N.; Herrera Arroyo, C.; Schuermans, C.; Bethge, W.; Engelhardt, M.; Kuball, J.; Michieli, M.; Schub, N.; Wilson, K. M. O.; Bourhis, J. H.; Mateos, M. V.; Robin, N.; Jost, E.; Kröger, N.; Moraleda, J. M. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 847 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. REAL‐WORLD RESULTS ON CD19 CAR T‐CELL FOR 60 FRENCH PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA INCLUDED IN A TEMPORARY AUTHORIZATION FOR USE PROGRAM. (12th June 2019) Authors: Thieblemont, C.; Le Gouill, S.; Di Blasi, R.; Cartron, G.; Morschhauser, F.; Bachy, E.; Paillassa, J.; Bernard, S.; Tessoulin, B.; Gastine, T.; Fegueux, N.; Kanouni, T.; Manier, S.; Sesques, P.; Houot, R.; Haouin, C.; Tilly, H.; Salles, G. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 301 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. S173: T-CELL ACTIVATION AND MYELOMA CELL KILLING CONFIRM THE MODE OF ACTION OF RG6234, A NOVEL GPRC5D T-CELL ENGAGING BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA. (23rd June 2022) Authors: Dekhtiarenko, I.; Lelios, I.; Attig, J.; Sleiman, N.; Lazzaro, D.; Clausen, I.; Gräfe, N.; Helms, H.-J.; Schindler, E.; Belli, S.; Fauti, T.; Eckmann, J.; Umana, P.; Jacob, W.; Schneider, M.; Hasselbalch Riley, C.; Hutchings, M.; Yoon, S.-S.; Koh, Y; Manier, S. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 74 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗